Bayer ($BAYZF) - Big Pharma's Q3 2010 Earnings Report

FiercePharma says: Bayer earned €280 million this quarter compared to €249 million the previous year, thanks primarily to its farm products and high-tech material divisons, as drug sales slowed despite good growth in emerging markets. Its birth control pill, Yaz, suffered due to increased generic competition. The company set aside €436 million for U.S. lawsuits, including €50 million for Yaz and Yasmin litigation.


  • Sales grow by 16.1 percent to EUR 8,581 million
  • EBITDA before special items up 10.5 percent to €1.656 million
  • Core earnings per share increase by 21.8 percent to €0.95
  • Provisions of €436 million established for litigations
  • Net financial debt reduced by €1.6 billion to €9.1 billion
  • Group outlook for 2010 confirmed

See Bayer's current stock quote from CNN Money

Bayer's website:
Full release: Bayer earnings release

Bayer ($BAYZF) - Big Pharma's Q3 2010 Earnings Report

Suggested Articles

The triple combo era in cystic fibrosis is here thanks to Vertex' new OK. Five months ahead of schedule, the FDA green-lighted Trikafta Monday.

On the heels of settling bellwether cases for $45 million, Teva is offering $250 million cash and $23 billion in drugs to end all its opioid lawsuits.

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.